Phreesia (PHR) Insider Lainie Goldstein Buys $185K of Stock

Phreesia Insider Trade by Lainie Goldstein

Lainie Goldstein bought 19,290 shares of Phreesia, Inc. (NYSE:PHR) on June 24, 2026. The shares were acquired at $9.59 apiece, bringing the total value of the transaction to $184,991. This purchase formed part of a broader wave of insider buying on the exact same day, with peers such as Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, Ramin Sayar, and Smith Mark Douglas each acquiring the exact same number of shares at the identical price.

Phreesia Stock Performance

Phreesia shares recently changed hands at $10.07, sitting well within a 52-week trading range spanning from a low of $7.77 to a high of $25.00. The stock maintains a market capitalization of roughly $622.57 million and a beta of 0.86, pointing to slightly lower volatility than the broader market. Its 50-day moving average sits at $11.15, while the 200-day moving average rests at $11.81.

Phreesia Earnings and Financial Health

Phreesia posted annual revenue of $507.79 million alongside a revenue growth rate of 10.4%. The company reported earnings per share of $0.18, accompanied by a net margin of 2.06% and a return on equity of 3.12%. Its current ratio stands at 1.76, while the quick ratio is 1.44 and the debt-to-equity ratio is 18.27. The trailing P/E ratio is 55.72, and the forward P/E ratio comes in at 6.24. The company's next earnings report is scheduled for December 7, 2026.

Phreesia Insider Transactions

The purchase by Lainie Goldstein arrived alongside identical transactions filed on June 24, 2026. Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, Ramin Sayar, and Smith Mark Douglas each acquired 19,290 shares at $9.59 per share for a matching total of $184,991 per transaction. None of these purchases were made under pre-arranged Rule 10b5-1 trading plans.

Analysts Set New Price Targets

Wall Street firms maintain diverse outlooks on Phreesia shares. On October 12, 2026, Barclays maintained its Equal-Weight rating while lifting its price target to $11.00 from $10.00. Earlier, on September 8, 2026, Raymond James downgraded the stock to Market Perform. DA Davidson maintained a Buy rating with a target lowered to $13.00 on September 4, 2026. Baird kept a Neutral rating at $11.00 on September 4, 2026, while Freedom Capital Markets maintained a Buy rating with a $14.00 target on September 3, 2026. RBC Capital reiterated an Outperform rating with a $19.00 target on September 3, 2026. Wells Fargo maintained an Equal-Weight rating and raised its target to $10.00 on September 3, 2026, and Canaccord Genuity kept a Buy rating with a $16.00 target on the same day. Overall, the stock carries a consensus Buy rating with a mean price target of $13.94 across 16 analyst opinions.

Inside Phreesia's Healthcare Software Business

Phreesia, Inc. provides an integrated software and payment platform designed for the healthcare industry across the United States and Canada. The company builds tools that help ambulatory practices, health systems, hospitals, and life sciences organizations manage appointment scheduling, patient intake, digital clinical data capture, and payment collections. Founded in 2005 and headquartered in Wilmington, Delaware, the firm focuses on streamlining administrative workflows for medical providers while offering flexible financing options to patients.

What to Watch Next for Phreesia

Investors will look toward Phreesia's upcoming earnings release on December 7, 2026, for updated revenue and profitability figures. Market participants will also monitor whether additional insiders follow up on June's purchases with further open-market transactions. As always, insider transactions provide a window into executive sentiment but do not guarantee future stock price movements.